DK0858504T3 - Diagnostiske midler mod og behandlinger af periodontale sygdomme - Google Patents

Diagnostiske midler mod og behandlinger af periodontale sygdomme

Info

Publication number
DK0858504T3
DK0858504T3 DK96934198T DK96934198T DK0858504T3 DK 0858504 T3 DK0858504 T3 DK 0858504T3 DK 96934198 T DK96934198 T DK 96934198T DK 96934198 T DK96934198 T DK 96934198T DK 0858504 T3 DK0858504 T3 DK 0858504T3
Authority
DK
Denmark
Prior art keywords
complex
prtr
prtk
remedies
treatments
Prior art date
Application number
DK96934198T
Other languages
Danish (da)
English (en)
Inventor
Eric Charles Reynolds
Peter Singh Bhogal
Nada Slakeski
Original Assignee
Univ Melbourne
Victorian Dairy Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Melbourne, Victorian Dairy Ind filed Critical Univ Melbourne
Application granted granted Critical
Publication of DK0858504T3 publication Critical patent/DK0858504T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK96934198T 1995-10-30 1996-10-30 Diagnostiske midler mod og behandlinger af periodontale sygdomme DK0858504T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN6275A AUPN627595A0 (en) 1995-10-30 1995-10-30 Diagnostics and treatments of periodontal disease

Publications (1)

Publication Number Publication Date
DK0858504T3 true DK0858504T3 (da) 2006-02-13

Family

ID=3790602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96934198T DK0858504T3 (da) 1995-10-30 1996-10-30 Diagnostiske midler mod og behandlinger af periodontale sygdomme

Country Status (13)

Country Link
US (3) US6511666B1 (https=)
EP (1) EP0858504B1 (https=)
JP (1) JP4117026B2 (https=)
KR (1) KR100286055B1 (https=)
AT (1) ATE312909T1 (https=)
AU (2) AUPN627595A0 (https=)
CA (1) CA2235224C (https=)
DE (1) DE69635582T2 (https=)
DK (1) DK0858504T3 (https=)
ES (1) ES2255082T3 (https=)
NZ (1) NZ320015A (https=)
WO (1) WO1997016542A1 (https=)
ZA (1) ZA969130B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0735293U (ja) * 1993-12-10 1995-06-27 株式会社松島製作所 もやいの照明装置
US20030157637A1 (en) * 1998-09-15 2003-08-21 The University Of Melbourne Diagnostics and treatments of periodontal disease
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
AUPO652897A0 (en) * 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
ES2377751T3 (es) * 1997-12-10 2012-03-30 Csl Limited Polipéptidos y polinucleótidos de Porfiromonas gingivalis
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
AUPP893999A0 (en) * 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
AUPQ718200A0 (en) 2000-04-28 2000-05-25 Csl Limited Porphyromonas gingivalis recombinant proteins and truncations
SE0400191D0 (sv) * 2004-01-30 2004-01-30 Tendera Ab A test kit for detecting periodontal disease
EP1799705A4 (en) * 2004-09-23 2008-11-05 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
AU2005287884B2 (en) * 2004-09-23 2010-12-02 The University Of Melbourne Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection
AU2007204730B2 (en) 2006-01-10 2011-11-17 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
CA2652957A1 (en) 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
US20100297179A1 (en) 2007-07-12 2010-11-25 Stuart Geoffrey Dashper Immunology Treatment for Biofilms
WO2009006699A1 (en) 2007-07-12 2009-01-15 Oral Health Australia Pty Ltd Biofilm treatment
DK2328914T3 (en) * 2008-08-29 2017-07-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P. gingivalis infection
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
SG11202003147XA (en) 2017-10-12 2020-05-28 Vaxcyte Inc Periodontitis vaccine and related compositions and method of use
CN111172177B (zh) 2019-07-30 2023-08-08 镇江市江澜绿洲生物技术有限公司 cra4S1基因及其编码的蛋白和应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830710A (en) 1988-09-08 1998-11-03 University Of Florida Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease
WO1995000110A1 (en) * 1993-06-28 1995-01-05 Lion Corporation Composition for oral cavity
US5523390A (en) * 1993-09-10 1996-06-04 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
WO1995007286A1 (en) 1993-09-10 1995-03-16 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase coding sequences
US5475097A (en) 1993-10-21 1995-12-12 University Of Georgia Research Foundation, Inc. Lysine-specific Porphyromonas gingivalis proteinase
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
AUPO652897A0 (en) * 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis

Also Published As

Publication number Publication date
EP0858504A1 (en) 1998-08-19
AU7267396A (en) 1997-05-22
JP2000510817A (ja) 2000-08-22
NZ320015A (en) 1999-02-25
ATE312909T1 (de) 2005-12-15
US20070189982A1 (en) 2007-08-16
KR100286055B1 (ko) 2001-05-02
US6511666B1 (en) 2003-01-28
KR19990067167A (ko) 1999-08-16
JP4117026B2 (ja) 2008-07-09
AUPN627595A0 (en) 1995-11-23
CA2235224C (en) 2011-11-29
CA2235224A1 (en) 1997-05-09
EP0858504B1 (en) 2005-12-14
AU715456B2 (en) 2000-02-03
US20110213129A1 (en) 2011-09-01
ZA969130B (en) 1997-06-24
EP0858504A4 (en) 2002-12-04
ES2255082T3 (es) 2006-06-16
WO1997016542A1 (en) 1997-05-09
DE69635582T2 (de) 2006-08-17
DE69635582D1 (de) 2006-01-19

Similar Documents

Publication Publication Date Title
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
CY1110128T1 (el) Καταλυτικα μονοκλωνικα αντισωματα με δραστικοτητα πρωτεασης για την εκλεκτικη λυση του πρωτεϊνικου συστατικου των πλακων και συνονθυλευματων που σχετιζονται με παθολογικες καταστασεις
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
CY1108007T1 (el) Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
EP1539228A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
ATE257390T1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
BR9814276A (pt) Antìgenos de superfìcie
ATE215379T1 (de) Antifungaleverfahren und mitteln
DE69614373D1 (de) Reinigungsemulsionen
ATE226442T1 (de) Anti-chlamydia verfahren und mittel
ES2216055T3 (es) Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob.
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ES2052893T3 (es) Preparado de n-acetil-glucosamina para administracion por via bucal.
DE69127334D1 (de) Verabreichung von Mitteln
DE68908117D1 (de) N-acetylglukosamin als zytoprotektives mittel.
BR9708027A (pt) Métodos de tratamento ou prevenção de cistite entersticial
ATE338819T1 (de) Antigenes protein aus malassezia
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
KR910006478A (ko) 인체 트립타제 유사 단백질